Ozurdex launched in China for RVO

Ozurdex launched in China for RVO

Colin Kerr

Published: Tuesday, May 1, 2018

Allergan has announced the launch of Ozurdex (dexamethasone intravitreal implant 0.7mg) in China for the treatment of adult patients with macular oedema secondary to retinal vein occlusion (RVO). Ozurdex is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular oedema following BRVO and CRVO. “Providing millions of RVO patients access to Ozurdex is a significant step towards preventing blindness and meeting a critical unmet need in China,” said Marc Princen, Allergan International President. http://www.allergan.com/

Latest Articles

Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Update on Astigmatism Analysis

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

iNovation Innovators Den Boosts Eye Care Pioneers

New ideas and industry, colleague, and funding contacts among the benefits.

From Concept to Clinic

Partnerships with academia and industry promote innovation.

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

How Many Surgeries Equal Surgical Proficiency?

Internet, labs, simulators, and assisting surgery all contribute.